The ability to detect
cancer early in an accurate and rapid fashion
is of critical importance for cancer diagnosis and accurate resection
in surgery. γ-Glutamyltranspeptidase (GGT) is overexpressed
in several human cancers, while maintaining a low expression in normal
microenvironments, and thus is recognized as an important cancer biomarker.
To date, rational design of a zero cross-talk ratiometric near-infrared
(NIR) GGT fluorescent probe for efficient cancer diagnosis in various
biological samples is still a big challenge. In this work, a zero
cross-talk ratiometric NIR GGT fluorescent probe named Cy-GSH is developed.
Cy-GSH shows high sensitivity to GGT, which is desired for early cancer
diagnosis. Upon additional GGT, a large emission shift from 805 to
640 nm is observed, which is suitable for visualizing deeply located
cancer in vivo. In addition, successful monitoring of GGT activity
in blood, cells, tissues, and in vivo makes Cy-GSH possess great potential
for the clinical cancer early diagnosis. Furthermore, accurately visualizing
tumors and metastases in mouse models illuminates that the probe may
be a convenient tool for fluorescence-guided cancer surgery. To our
knowledge, this is the first report to describe the strategy of a
zero cross-talk ratiometric NIR GGT fluorescent probe for early cancer
diagnosis and fluorescence-guided surgery.